Literature DB >> 24843223

Vestibular assessment in patients with vestibular schwannomas: what really matters?

R Teggi1, A Franzin2, G Spatola2, N Boari2, P Picozzi2, M Bailo2, L O Piccioni1, F Gagliardi2, P Mortini2, M Bussi1.   

Abstract

Vestibular function is often underdiagnosed in vestibular schwannomas (VS). To evaluate it in a selected group of patients harbouring vestibular schwannomas, 64 patients were included in this study, recruited between March 2008 and June 2011 at our institution. All patients underwent Gd-enhanced MRI and complete neurotological evaluation before gamma knife surgery. Morphological measurements included Koos Classification and quantification of internal acoustic canal filling in length and diameter. Cochlear and vestibular functions were assessed considering pure tone and speech audiometry, bedside examination and caloric test by videonystagmography. A statistical analysis was performed to find possible correlations between morphological and cochleovestibular data. Patients with a higher intracanalicular length (ICL, mean value 8.59 and median 8.8 mm) of the tumour presented a higher value of UW than the subgroup with a lower length (51.9 ± 24.3% and 38.8 ± 18.1% respectively, p = 0.04), while no difference was detected for pure tone audiometry (PTA) values (50.9 ± 22.3 db and 51.1 ± 28.9 db respectively). Patients with a higher ICL also presented a higher rate of positive HIT (88% and 60% respectively, p = 0.006). Patients with a higher value of intracanalicular diameter (ICD, mean value 5.22 and median 5.15 mm) demonstrated higher values of UW (50.2 ± 29.1% and 39.3 ± 21% respectively, p = 0.03), but not different PTA (50.2 ± 29.1 db and 51.9 ± 29.9 db respectively). Finally, patients with a positive head impulse test (HIT) demonstrated significantly higher values of unilateral weakness (UW) (p = 0.001). Vestibular disorders are probably underdiagnosed in patients with VS. ICL and ICD seem to be the main parameters that correlate with vestibular function. Also, in case of small intracanalar T1 VS a slight increase of these variables can result in significant vestibular impairment. The data reported in the present study are not inconsistent with the possibility of proactive treatment of patients with VS.

Entities:  

Keywords:  Gamma-Knife; Hearing loss; Radiosurgery; Vestibular Schwannomas; Vestibular tests

Mesh:

Year:  2014        PMID: 24843223      PMCID: PMC4025177     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  36 in total

1.  Prospective evaluation of the clinical profile and referral pattern differences of vestibular schwannomas and other cerebellopontine angle tumors.

Authors:  Ahmed Ragab; Afaf Emara; Maged Shouker; Osama Ebied
Journal:  Otol Neurotol       Date:  2012-07       Impact factor: 2.311

2.  Correlation between caloric and ocular vestibular evoked myogenic potential test results.

Authors:  Chi-Hsuan Huang; Shou-Jen Wang; Yi-Ho Young
Journal:  Acta Otolaryngol       Date:  2011-11-06       Impact factor: 1.494

3.  Longitudinal analysis of hearing before and after radiosurgery for vestibular schwannoma.

Authors:  Shoji Yomo; Romain Carron; Jean-Marc Thomassin; Pierre-Hugues Roche; Jean Régis
Journal:  J Neurosurg       Date:  2012-08-31       Impact factor: 5.115

4.  Expectant management of vestibular schwannoma: a retrospective multivariate analysis of tumor growth and outcome.

Authors:  Mark Hughes; Christopher Skilbeck; Shakeel Saeed; Robert Bradford
Journal:  Skull Base       Date:  2011-09

5.  Correlating the cochleovestibular deficits with tumor size of acoustic neuroma.

Authors:  An-Shiou Day; Chi-Te Wang; Chun-Nan Chen; Yi-Ho Young
Journal:  Acta Otolaryngol       Date:  2008-07       Impact factor: 1.494

6.  Conservative treatment of vestibular schwannoma: a follow-up study on clinical and quality-of-life outcome.

Authors:  Willem P Godefroy; Adrian A Kaptein; Justine J Vogel; Andel G L van der Mey
Journal:  Otol Neurotol       Date:  2009-10       Impact factor: 2.311

7.  Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC.

Authors: 
Journal:  Otolaryngol Head Neck Surg       Date:  1995-09       Impact factor: 3.497

8.  Vestibular function and quality of life in vestibular schwannoma: does size matter?

Authors:  Judith Nastjenka Wagner; Miriam Glaser; Berndt Wowra; Alexander Muacevic; Roland Goldbrunner; Christian Cnyrim; Jörg-Christian Tonn; Michael Strupp
Journal:  Front Neurol       Date:  2011-08-30       Impact factor: 4.003

9.  Hearing preservation surgery in acoustic neuroma. Slow progress and new strategies.

Authors:  A Mazzoni; F Biroli; C Foresti; A Signorelli; C Sortino; E Zanoletti
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-04       Impact factor: 2.124

10.  Hearing preservation surgery in acoustic neuroma: long-term results.

Authors:  A Mazzoni; E Zanoletti; V Calabrese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-04       Impact factor: 2.124

View more
  4 in total

Review 1.  Evaluation of Vestibular Function in Diagnosis of Vestibular Schwannomas.

Authors:  Xue-Qing Zhang; Tai-Sheng Chen; Wei Wang
Journal:  Curr Med Sci       Date:  2021-08-17

2.  Audiovestibular Function Deficits in Vestibular Schwannoma.

Authors:  Constantin von Kirschbaum; Robert Gürkov
Journal:  Biomed Res Int       Date:  2016-09-22       Impact factor: 3.411

3.  Sensitivity and specificity of vestibular bed-side examination in detecting VIII cranial nerve schwannoma with sensorineural sudden unilateral hearing loss as presenting symptom.

Authors:  L Califano; F Salafia; M G Melillo; S Mazzone
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-08       Impact factor: 2.124

4.  Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.

Authors:  Jinlu Gan; Yanling Zhang; Jingnan Wu; Deqiang Lei; Fangcheng Zhang; Hongyang Zhao; Lei Wang
Journal:  Front Oncol       Date:  2021-08-12       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.